Introduction
Candida species are the most common cause of human fungal infections, causing a range of debilitating mucocutaneous infections to life-threatening invasive diseases.
Among Candida spp., Candida albicans is the most common infectious agent, and a frequent cause of fungal genitourinary diseases such as vulvovaginal candidiasis, which is diagnosed in up to 40% of women with vaginal complaints in the primary care settings 1 . In a hospital setting, hematogenously disseminated candidiasis represents the third-to-fourth most common nosocomial infection worldwide, and C. albicans remains the main etiological agent of invasive candidiasis accounting for over half of all cases 2 . Hematogenously disseminated candidiasis is life threatening, with associated mortality rates between 30 and 60%, despite antifungal use 3 .
The success of C. albicans as a pathogen is due to its possessing a number of virulence characteristics, including avid adherence to both abiotic and host cell surfaces 4 , the capacity to grow tissue-invading filaments 5 , and the ability to develop biofilms that are resistant to both immune cells and antifungal therapy 6 . Blocking any of these key virulence traits could serve as the basis of novel therapeutic interventions, with minimal impact on the commensal homeostasis, and reduced selection pressures for emergence of drug resistance 7 .
Als3p is a vital protein for C. albicans virulence. Expressed on the hyphae, Als3p governs all the aforementioned traits (adherence, invasion and biofilms formation) that lead to host pathogenesis 8, 9 . Als3p is also required for iron uptake from the host 10 . Our group has used Als3p for the development of an antiCandida funga vaccinel called NDV-3A
11
. NDV-3, containing a His-tagged recombinant version of the C. albicans Als3 protein N-terminus (rAls3p-N), formulated with alum, prevents both mucosal and hematogenously disseminated candidiasis in mice [12] [13] [14] [15] . NDV-3 was highly immunogenic, well-tolerated and had minimal minor side effects in a Phase I clinical trial 16 . Furthermore, the latest version of the vaccine, prepared with rAls3p-N without the His-tag, formulated with alum, (NDV-3A), was equally safe and immunogenic, and protective against vaginal infections, in an exploratory 1b/2a clinical trial of patients with a history of recurrent vulvovaginal candidiasis (RVVC) 11 . Subsequently, our group showed that serum antibodies from patients who responded to NDV-3A (but not those of the unresponsive patients) could prevent C.
albicans adhesion and biofilm formation on plastic, and invasion of vaginal epithelial cells, in vitro.
These phenotypic assays served as surrogate markers for efficacy of the NDV-3A vaccine in patients with RVVC NDV-3A vaccinated and catheterized mice were infected with C. albicans intravenously.
Catheterized mice vaccinated with alum alone and infected similarly, served as placebo. Three days post infection, NDV-3A vaccination resulted in ~ 1.5 log reduction in catheter and 0.7 log reduction in kidney fungal burden, respectively (Fig 1B) , when compared to placebo-vaccinated mice (kidneys p=0.0006 and catheters p=0.04).
NDV-3A vaccination prevented C. albicans virulence traits, and abrogated biofilm dispersal
Because vaccination yielded high levels of rAls3p-N-specific IgG which were accompanied with 50%, compared to alum vaccinated sera ( Fig 1C) . Next, we examined if anti-rAls3p-N antibodies could block biofilm growth on silicone elastomer catheter material. We showed that NDV-3A
vaccinated serum abrogated at least 50% of biofilm growth, when added at the time of biofilm initiation, compared to when biofilms were developed in the presence of alum-vaccinated serum (Fig 1D) . The sera however failed to kill or disrupt preformed biofilms (data not shown). C.
albicans biofilms form a robust mesh of yeast and hyphal cells encased in an extracellular matrix, inert to almost all classes of antifungal drugs as well as resistant to immune cell attack 6 . Our finding that anti-rAls3p-N antibodies prevented adhesion, invasion and biofilm formation is not without premise. First, the sera were heat treated to rule out a role for complement in the experimental outcome. Second, we previously demonstrated that NDV-3A protects mice from VVC by a mechanism that involves the priming of both humoral and adaptive immune responses 12 .
The importance of antibodies targeting virulence traits of C. albicans was also demonstrated in animal models against other important antigens including Hyr1p 18, 19 , Sap2
20
, and Candida cell wall glycopeptides 21, 22 . Our results show that murine (this study) and human anti-rAls3p-N antibodies display enhanced efficacy at neutralizing C. albicans Als3-associated primary functions of adhesion, invasion and biofilm formation. . Although the antibodies induced by NDV-3A were inactive with fully formed biofilm, incubation with NDV-3A derived antisera prevented formation of lateral yeast cells, thus reducing dispersal of yeast cells from the biofilms, compared to both biofilms treated with sera from alum-vaccinated mice, and commercially available sera (Fig 2A) . Specifically, the serum from mice immunized with NDV-3A reduced lateral yeast cell dispersal by 35% (Fig 2B, p=0.001 ).
Overall, these results highlight the potential of NDV-3A vaccination to not only prevent disseminated infections, but also to block the source of dissemination, since biofilms act as a reservoir of dispersing cells directly into the blood stream 24 . This finding also suggests a role of Als3p, an abundant hyphal cell-surface protein, in lateral yeast cell growth from hyphae.
Collectively, these in vitro and in vivo studies serve as evidence for the role of antibodies in abrogating disseminated candidiasis. The NDV-3A vaccination induced significant abrogation of C. albicans pathogenic traits and reduced subsequent lethality. While this inhibition of virulence traits or protection from candidiasis was not 100%, we submit that this vaccine is not expected to be used as an isolated therapeutic option alone. We postulate that the preventative activity exhibited by vaccination can be further augmented in the presence of antifungal drugs. It is possible that such a combination of the vaccine with antifungal drugs would allow the usage of smaller quantities of antifungal drugs, thereby inhibiting the evolution of antifungal drug resistance. This hypothesis is the subject of future studies by our group.
In summary, our study illuminates the broad therapeutic relevance of anti-rAls3p-N antibodies generated after vaccination, in preventing C. albicans virulence both in vitro and in vivo, including device-associated candidiasis. These studies also include efforts to directly target a specific virulence determinant influencing host-pathogen interactions. We hope to provide additional concepts for further developing vaccination strategies for fungal pathogens in general. Currently, no vaccines have been approved for human fungal pathogens. . NDV-3A was kindly provided by NovaDigm Inc., where the vaccine was generated. anti-alum sera were plotted as percent invasion compared to IgG isotype control sera.
Material and methods

Candida
Mice immunizations and infection models:
Biofilm-related assays: Biofilms were developed on silicone elastomer (SE) pieces, in the presence/absence of serum, with modifications 23 . Briefly, circular SE pieces with the approximate diameter of a 96-well were prepared by punching the SE sheets with a paper puncher. These autoclaved and sterile SE circles were pre-incubated with 100% fetal bovine serum overnight at room temperature, washed twice with sterile water, and then introduced into the wells of a 96-well plate, where they fit snugly. C. albicans blastospores (2 × 10 5 cells/ml in YNB medium) were added to wells containing 5 µL of respective NDV-3A , alum vaccinated mice sera or commercial serum (each 5% serum vol/vol), and incubated at 37°C. Biofilm was then allowed to develop in the SE-bottomed wells for 24 h at 37 o C, washed once with sterile water, and estimated using the XTT calorimetric assay, that measures the metabolic activity of the cells 27 . Data was plotted as percent reduction in biofilm growth versus the control.
For measuring the impact of anti-rAls3p-N antisera on biofilm dispersal, C. albicans biofilms were developed for 6 h in 96-well microtiter plates, after which the wells were washed twice with sterile water. YNB medium with 5% sera from NDV-3A or alum-vaccinated mice, and commercially available serum (as control) was added to the wells, and the biofilms allowed to grow for another 12 h at 37 o C. Media over the biofilms were aspirated and turbidity (OD600) quantified. At the same time, aliquots of biofilms were placed on a glass slide to visualize under a bright field microscope at 40X magnification, and images captured.
Statistical Analysis: All in vitro studies were performed in triplicate at a minimum, with two biological replicates. Different groups were compared using the non-parametric Mann-Whitney test for comparison of unmatched groups. Data were analyzed in GraphPad Prism software (La Jolla, CA, USA), and a p-value <0.05 was considered statistically significant.
For in vivo studies, a power analysis for a two-tailed students t-test was used which results in a 90% power to detect a log difference in tissue and catheter fungal burden.
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